COMMISSION IMPLEMENTING REGULATION (EU) 2020/2105

of 15 December 2020


(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,


Whereas:


(2) Active substances included in Annex I to Directive 91/414/EEC are deemed to have been approved under Regulation (EC) No 1107/2009 and are listed in Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011 (4).


(4) An application for the renewal of the approval of the active substance etoxazole was submitted in accordance with Article 1 of Commission Implementing Regulation (EU) No 844/2012 (5) within the time period provided for in that Article.

(5) The applicant submitted the supplementary dossiers required in accordance with Article 6 of Implementing Regulation (EU) No 844/2012. The application was found to be complete by the rapporteur Member State.

(6) The rapporteur Member State prepared a draft renewal assessment report in consultation with the co-rapporteur Member State and submitted it to the European Food Safety Authority ('the Authority') and the Commission on 20 September 2016.

(7) The Authority made the supplementary summary dossier available to the public. The Authority also circulated the draft renewal assessment report to the applicant and to the Member States for comments and launched a public consultation on it. The Authority forwarded the comments received to the Commission.

On 12 September 2017, the Authority communicated to the Commission its conclusion (6) on whether etoxazole can be expected to meet the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009. The Commission presented a renewal report and the draft Regulation for etoxazole on 21 March 2018 and a revised version of the renewal report in March 2020 to the Standing Committee on Plants, Animals, Food and Feed.

As regards the criteria to identify endocrine disrupting properties introduced by Commission Regulation (EU) 2018/605 (7), the conclusion of the Authority indicates that, based on the scientific evidence, it is highly unlikely that etoxazole is an endocrine disruptor via the estrogenic, androgenic and thyroidogenic modalities. Furthermore, the available evidence indicates that etoxazole is unlikely to be an endocrine disruptor via the steroidogenic modality. Thus, the Commission concludes that etoxazole is not to be considered as having endocrine disrupting properties.

The Commission invited the applicant to submit its comments on the conclusion of the Authority and, in accordance with the third paragraph of Article 14(1) of Implementing Regulation (EU) No 844/2012, on the renewal report. The applicant submitted its comments on both versions of the renewal report, which have been carefully examined.

It has been established with respect to one or more representative uses of at least one plant protection product containing the active substance etoxazole that the approval criteria provided for in Article 4 of Regulation (EC) No 1107/2009 are satisfied.

The Commission, however, considers that etoxazole is a candidate for substitution pursuant to Article 24 of Regulation (EC) No 1107/2009. Etoxazole is considered a bioaccumulative and toxic substance in accordance with points 3.7.2.2 and the first sub point of 3.7.2.3 of Annex II to Regulation (EC) No 1107/2009. Etoxazole therefore fulfils the condition set in the second indent of point 4 of Annex II to Regulation (EC) No 1107/2009.

It is therefore appropriate to renew the approval of etoxazole as a candidate for substitution pursuant to Article 24 of Regulation (EC) No 1107/2009.

The risk assessment for the renewal of the approval of the active substance etoxazole is based on representative uses as an acaricide. While it is not necessary, in the light of this risk assessment, to maintain the restriction to use only as an acaricide, it is, however, necessary to provide, in accordance with Article 14(1) of Regulation (EC) No 1107/2009 in conjunction with Article 6 thereof and in the light of current scientific and technical knowledge, for certain conditions and restrictions. It is, in particular, appropriate to restrict the use of plant protection products containing etoxazole to use on ornamental plants in permanent greenhouses. The restriction to ornamentals aims to exclude any dietary exposure of consumers because the risk assessment for processed commodities could not be finalised and uncertainties are too high. As high risk was identified to aquatic organisms, non-target arthropods and soil mites, the restriction to greenhouses as defined in Article 3 of Regulation (EC) No 1107/2009 aims to avoid exposure to the environment and non-target organisms.

In order to increase the confidence in the conclusion that etoxazole does not have endocrine disrupting properties, the applicant should provide an updated assessment, in accordance with point 2.2(b) of Annex II to Regulation (EC) No 1107/2009, of the criteria laid down in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, and in accordance with the guidance for the identification of endocrine disruptors (8).

Implementing Regulation (EU) No 540/2011 should therefore be amended accordingly.

Article 1

Renewal of the approval of the active substance

The approval of the active substance etoxazole is renewed as set out in Annex I.

Article 2

Amendments to Implementing Regulation (EU) No 540/2011

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with Annex II to this Regulation.

Article 3

Entry into force and date of application

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

It shall apply from 1 February 2021.

This Regulation shall be binding in its entirety and directly applicable in all Member States.


For the Commission

The President

Ursula VON DER LEYEN

<table>
<thead>
<tr>
<th>Common Name, Identification Numbers</th>
<th>IUPAC Name</th>
<th>Purity (1)</th>
<th>Date of approval</th>
<th>Expiration of approval</th>
<th>Specific provisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>etoxazole CAS No 153233-91-1 CIPAC No 623</td>
<td>(RS)-5-tert-butyl-2-[(2,6-difluorophenyl)-4,5-dihydro1,3-oxazol-4-yl]phenetole</td>
<td>≥ 948 g/kg</td>
<td>1 February 2021</td>
<td>31 January 2028</td>
<td>Only uses on ornamental plants in permanent greenhouses shall be authorised. For the implementation of the uniform principles, as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the renewal report on etoxazole, and in particular Appendices I and II thereto, shall be taken into account. In this overall assessment Member States shall pay particular attention to: — possible uptake of persistent soil metabolites in rotational crops; — the protection of operators, ensuring that conditions of use include the application of adequate personal protective equipment. The applicant shall submit to the Commission, the Member States and the Authority by 5 January 2023 confirmatory information as regards points 3.6.5 and 3.8.2 of Annex II of Regulation (EC) No 1107/2009 including an updated assessment of the information already submitted and, where relevant, further information.</td>
</tr>
</tbody>
</table>

(1) Further details on the identity and the specification of the active substance are provided in the renewal report.
The Annex to Commission Implementing Regulation (EU) No 540/2011 is amended as follows:

1. In Part A, entry 99 on etoxazole is deleted;
2. In Part E, the following entry is added:

<table>
<thead>
<tr>
<th>No</th>
<th>Common Name, Identification Numbers</th>
<th>IUPAC Name</th>
<th>Purity (g/kg)</th>
<th>Date of approval</th>
<th>Expiration of approval</th>
<th>Specific provisions</th>
</tr>
</thead>
</table>
| '13 | etoxazole CAS No 153233-91-1 CIPAC No 623 | (RS)-5-tert-butyl-2-(2,6-difluorophenyl)-4,5-dihydro1,3-oxazol-4-ylphenetole | ≥ 948 | 1 February 2021 | 31 January 2028 | Only uses on ornamental plants in permanent greenhouses shall be authorised.
For the implementation of the uniform principles, as referred to in Article 29(6) of Regulation (EC) No 1107/2009, the conclusions of the renewal report on etoxazole, and in particular Appendices I and II thereto, shall be taken into account.
In this overall assessment Member States shall pay particular attention to:
— possible uptake of persistent soil metabolites in rotational crops;
— the protection of operators, ensuring that conditions of use include the application of adequate personal protective equipment.
The applicant shall submit to the Commission, the Member States and the Authority by 5 January 2023 confirmatory information as regards points 3.6.5 and 3.8.2 of Annex II of Regulation (EC) No 1107/2009, including an updated assessment of the information already submitted and, where relevant, further information.'

(1) Further details on the identity and the specification of the active substance are provided in the renewal report.